GlobeNewswire

Cornell receives $35M to support cassava development for smallholder farmers in sub-Saharan Africa

Dela

Ithaca, New York, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Cassava is vital to the food security of millions of Africans who eat some form of the root crop daily. Although cassava breeders are making progress, they still face significant challenges in developing disease-resistant varieties that also increase overall yield and respond to the needs of smallholder farmers and processors. Cornell University will expand international efforts to deliver improved varieties of cassava to smallholder farmers in sub-Saharan Africa with $35 million in new funding from the Bill & Melinda Gates Foundation and UK aid from the United Kingdom.

"This grant funds a second five-year phase that will allow us to build on previous work and focus on getting improved varieties into farmers' fields," said Ronnie Coffman, international plant breeder and director of Cornell's International Programs in the College of Agriculture and Life Sciences, who leads the project. 

During Phase 1 of the Next Generation Cassava Breeding project - also funded by the Gates Foundation and UK aid from 2012 to 2017 - researchers shortened the breeding cycle for new cassava varieties by improving flowering and using genomic selection. Through analyzing plant genotypes and identifying cassava lines with desirable traits, such as resistance to cassava brown streak disease or high dry matter content, breeders also improved their ability to make selections based on genetics and probability without having to wait for seedlings to reach adulthood. These methods save breeding time for a crop where flowering and sexual propagation are issues.

Another goal of Phase 1 was to make cassava genomic information publicly accessible on an open database. Cassava researchers all over the world are now comparing results and improving breeding programs without duplicating efforts by using Cassavabase. To reduce cost per progeny and improve the quality of data uploaded to Cassavabase in Phase 2, NextGen researchers will use additional methods of whole genome sequencing. 

"Our focus for the next five years will be to translate this research into breeding practices to increase impact," said Chiedozie Egesi, NextGen project director and adjunct professor of plant breeding and genetics at Cornell, who is based at the International Institute of Tropical Agriculture (IITA) in Nigeria. "A key goal in Phase 2 will be to identify traits preferred by farmers and end-users and incorporate them into new cassava lines to ensure that varieties are responsive to people's needs."

Egesi said, "We believe we will accelerate genetic gain as well as adopted genetic gain, increase the yields and resilience of cassava production by smallholder farmers, and move African cassava breeding toward greater capacity."

"Among the 30 new clones developed at IITA using our methods, 10 had higher dry matter yield than any clone currently available for smallholder farmers in Nigeria," said Jean-Luc Jannink, a research plant geneticist with the United States Department of Agriculture, Agricultural Research Service  (USDA-ARS) and Cornell adjunct associate professor in the Department of Plant Breeding and Genetics at Cornell. "Dry matter yield is a close proxy to food yield. Conservatively, we believe that we will increase the rate of genetic gain in cassava by 30 to 50 percent." 

Said Peter Kulakow, IITA cassava breeder and geneticist: "Genetic gain is a measure of the improvement of plant performance between generations and a goal of most modern breeding programs. Swifter improvements mean more new varieties can be tested and released." 

At the sixth annual Next Gen Cassava meeting, Feb. 19-24 in Dar es Salaam, Tanzania, teams of NextGen breeders, geneticists, data analysts, computer programmers, food technologists, social scientists and crop protectionists will be focusing on goals for Phase 2 and discussing how to better coordinate and leverage the exchange of germplasm and genotypic and phenotypic data from each other.

Developing capacity for sustainable breeding programs

Compared with other major staples like maize, rice and wheat, cassava has undergone few advances in productivity and yield over the last 50 years, making it an ideal candidate for breeding improvement. Because cassava is clonally propagated and has a low multiplication rate, it can take almost six to eight years before a new cassava variety makes it from breeders' nurseries through field trials to farmers' fields. Most breeding efforts focus on product development  - goals set by scientists and researchers without accounting for the preferences of farmers. In practice, this can result in poor adoption of new varieties and unrealized potential. 

"Breeders must be able to more quickly develop cassava varieties that resist diseases, are climate resilient and meet the needs of end-users and consumers," said Egesi.

Strengthening the capacity of national breeding programs will be critical in achieving self-sustaining breeding systems in sub-Saharan Africa. Over the next five years, NextGen researchers will continue to train the next generation of sub-Sahara African cassava breeders in modern plant breeding techniques like genomic selection and improved breeding methods.

International and regional partnerships are another important element of sustainability. NextGen researchers are reaching out to their counterparts in Ghana, Rwanda, Mozambique, Sierra Leone and the Democratic Republic of Congo to create a broader network of researchers who can work together to improve livelihoods and food security.

In Africa, NextGen collaborators include the International Institute of Tropical Agriculture, the National Root Crops Research Institute and West Africa Centre for Crop Improvement in Nigeria; the National Crops Resources Research Institute and Makerere University in Uganda; and the Tanzania Agricultural Research Institute in Tanzania. In South America, collaborators include Embrapa in Brazil and the International Center for Tropical Agriculture in Colombia. In the US, collaborators are Cornell University (who leads the project), the Boyce Thompson Institute at Cornell, the University of Hawaii, and the USDA-ARS in Ithaca.

For more information see www.nextgencassava.org   

 

 

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1896398-975a-4943-85b0-4f4b165f5678

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e3e5f6e-d4b9-45d1-b74d-8248eb7bb1ba

Linda McCandless
Cornell University 
6072275920
llm3@cornell.edu



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cornell University via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum